In concordance with 2018 National Institute for Health and Care Excellence (NICE) guidelines, post-menopausal women with ER-positive invasive breast cancer should be offered extended endocrine therapy with an aromatase inhibitor after completing initial five years of tamoxifen therapy, provided the treatment was tolerated [7]. Here, CYP19A1 is linked to invasive breast carcinoma.